Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation
- Conditions
- Multiple Myeloma
- Interventions
- Drug: BortezomibDrug: CarmustineDrug: EtoposideDrug: CytarabineDrug: MelphalanProcedure: Stem cell infusion
- First Posted Date
- 2012-07-31
- Last Posted Date
- 2014-10-15
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 10
- Registration Number
- NCT01653418
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
A Study of RO5429083 Alone or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia
- First Posted Date
- 2012-07-16
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 44
- Registration Number
- NCT01641250
Tosedostat and Cytarabine or Azacitidine in Treating Older Participants With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- Conditions
- High Risk Myelodysplastic SyndromeAcute Myeloid Leukemia
- Interventions
- First Posted Date
- 2012-07-10
- Last Posted Date
- 2020-04-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT01636609
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study of RO5045337 in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia
- First Posted Date
- 2012-07-09
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 43
- Registration Number
- NCT01635296
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
- Conditions
- Acute Myeloid LeukemiaAdult Acute Basophilic LeukemiaAdult Acute Monoblastic LeukemiaAdult Acute Monocytic LeukemiaAdult Acute Myeloid Leukemia With MaturationAdult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLLAdult Acute Myeloid Leukemia Without MaturationAdult Acute Myelomonocytic LeukemiaAlkylating Agent-Related Acute Myeloid LeukemiaSecondary Acute Myeloid Leukemia
- Interventions
- Drug: CytarabineDrug: Daunorubicin HydrochlorideOther: Laboratory Biomarker AnalysisDrug: DecitabineOther: Pharmacological Study
- First Posted Date
- 2012-06-25
- Last Posted Date
- 2021-06-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 178
- Registration Number
- NCT01627041
- Locations
- 🇺🇸
Lafayette Family Cancer Center-EMMC, Brewer, Maine, United States
🇺🇸NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant
- Conditions
- Acute Lymphoblastic LeukemiaChronic Myelocytic LeukemiaJuvenile Myelomonocytic LeukemiaHodgkin or Non-Hodgkin LymphomaSarcoma, MyeloidMyelodysplastic SyndromeAcute Myelocytic Leukemia
- Interventions
- Drug: clofarabineDrug: cytarabineDrug: busulfanDrug: PlerixaforDrug: cyclophosphamideDrug: antithymocyte globulin (rabbit)Biological: stem cellsDrug: TacrolimusDrug: mycophenolate mofetil
- First Posted Date
- 2012-06-18
- Last Posted Date
- 2017-02-20
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 34
- Registration Number
- NCT01621477
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Safety and Efficacy Study of Ara-c at 18 gm/m2 Versus 12 gm/m2 for 3 Cycles Each in AML Consolidation
- First Posted Date
- 2012-06-11
- Last Posted Date
- 2012-09-17
- Lead Sponsor
- All India Institute of Medical Sciences, New Delhi
- Target Recruit Count
- 180
- Registration Number
- NCT01615757
- Locations
- 🇮🇳
AIIMS, Delhi, India
A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
- Conditions
- Lymphoblastic Leukemia, Acute, ChildhoodPeripheral T-cell LymphomaLymphoblastic Lymphoma
- Interventions
- First Posted Date
- 2012-06-07
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
- Target Recruit Count
- 16
- Registration Number
- NCT01614197
- Locations
- 🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia, United States
🇺🇸Lurie Children's Hospital, Chicago, Illinois, United States
Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Monoblastic Leukemia (M5a)Adult Erythroleukemia (M6a)Adult Pure Erythroid Leukemia (M6b)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Refractory Anemia With Excess BlastsAdult Acute Myelomonocytic Leukemia (M4)Recurrent Adult Acute Myeloid LeukemiaAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Interventions
- First Posted Date
- 2012-05-30
- Last Posted Date
- 2017-03-31
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 7
- Registration Number
- NCT01607645
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- Conditions
- Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Secondary Myelodysplastic SyndromesAcute Myeloid Leukemia With Multilineage DysplasiaSecondary Acute Myeloid LeukemiaAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Previously Treated Myelodysplastic SyndromesUntreated Adult Acute Myeloid Leukemiade Novo Myelodysplastic Syndromes
- Interventions
- First Posted Date
- 2012-03-30
- Last Posted Date
- 2017-02-15
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 34
- Registration Number
- NCT01567059
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.